337 results about "Squamous carcinoma" patented technology

The diverse receptor-ligand pairs of the Wnt and frizzled (Fzd) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. The mRNA levels and expression levels of 5 Wnt (Wnt-1, 5a, 7a, 10b, 13) and 2 Fzd (Fzd-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC) were investigated. In addition, anti-Wnt-1 antibodies were used to study the Wnt / Fzd signalling pathway. These results indicate that HNSCC cell lines overexpress one or more Wnt and Fzd genes, and the proliferation and survival of a subset of HNSCC may depend on the Wnt / Fzd pathway. Therefore, the Wnt and Fzd receptors may be useful targets for immunotherapy of this common cancer.

The invention discloses a high-throughput multi-index protein chip for screening esophageal squamous carcinoma specific protein markers, and discloses a kit supporting the use. 55 types of esophageal squamous carcinoma differential proteins in the serum or blood plasma are selected and used as the esophageal squamous carcinoma protein markers and protein contrast prepare the protein chip; and the protein chip comprises a substrate, protein detection indicators and a contrast detection indicator coating, wherein the protein detection indicators are distributed as arrays on the substrate. Detection liquid of a supplementary experiment reagent is filled in the kit. By adopting the protein chip, the protein profiles of three types of people, namely, normal people, people subjected to esophageal squamous cell carcinoma precancerous lesions, and people subjected to the esophageal squamous carcinoma, can be determined; and means are provided for screening the esophageal squamous carcinoma in the early stage, diagnosing in mid stage and late stage, as well as monitoring the state of illness.

The invention discloses a serum protein marker for early screening and diagnosis of esophageal squamous carcinoma, and belongs to the field of biomedical technology. The serum protein marker is any one or a combination of two or more of proteins encoded by P53, GNA11, GNAS, PTEN, ACVR1B, FBXW7, EGFR, PDGFRA, SRSF2, MEN1, DAXX or CASP8 genes. Based on the role played by cancer driving genes in tumorigenesis and development, a human protein chip encoded by 138 cancer driving genes is customized, the human protein chip contains 180 human-derived recombinant proteins for screening out potential markers capable of diagnosing caners or other markers capable of characterizing cancers, early detection serum markers of the esophageal squamous carcinoma are primarily screened out by the protein chip, and then are verified by an ELISA indirect method experiment, a group of joint serum protein markers of esophageal squamous carcinoma for the early screening and diagnosis of the esophageal squamouscarcinoma is screened out at last for assisting the clinical diagnosis of the esophageal squamous carcinoma, so that the serum protein marker has better reference value.

The invention belongs to the technical field of medical oncology, and particularly discloses an autoantibody joint detection ELISA kit for early screening of esophageal squamous carcinoma. The kit comprises a solid-phase carrier and a tumor-associated antigen coated on the solid-phase carrier, wherein the tumor-associated antigen consists of P53, TP53, CDKN2B and NPM1. Furthermore, the kit comprises sample diluent, a second antibody, second antibody diluent, positive control serum, negative control serum, developing solution, stop solution and washing solution. The ELISA kit is capable of effectively detecting the esophageal squamous carcinoma, especially the early esophageal squamous carcinoma, has detection sensitivity up to 88.8% and specificity up to 86.3%, can be used for the large-scale screening of asymptomatic groups in high-risk areas of the esophageal squamous carcinoma, and is beneficial for the esophageal squamous carcinoma screening and early discovery of the asymptomatichigh-risk groups.

The invention belongs to the field of prognosis estimation and canceration risk prediction on clinic of molecular biology, and particularly relates to application of a molecule of a detection ANO1 protein in the preparation of a kit or a detection agent for the prognosis estimation and precancerous disease progression risk prediction of esophageal squamous carcinoma. The molecule expressed by the detection ANO1 protein can be a nucleic acid, a protein or a compound, thus showing that the ANO1 protein can be used as a molecular marker for the prognosis estimation and precancerous disease progression risk prediction of the esophageal squamous carcinoma.

The invention discloses a function of HOXD-AS1 in diagnosis and treatment of esophageal squamous carcinoma and relates to discovery, detection and application of long-chain noncoding RNA. According to the sequences of the long-chain noncoding RNA, a specific real-time quantitative PCR primer is designed and synthesized; a real-time quantitative PCR preparation is utilized to detect the expression level of the long-chain noncoding RNA in a clinical case specimen of the esophageal squamous carcinoma, and results show that the expression of the long-chain noncoding RNA in the esophageal squamous carcinoma is remarkably up-regulated and the expression level of the long-chain noncoding RNA is highly associated with both clinical stages and pathological N stages of an esophageal squamous carcinoma patient. The specific detection sequences disclosed by the invention are expected to be used for preparing the preparation for auxiliary diagnosis, curative effect prediction or prognosis judgment of the esophageal squamous carcinoma. In addition, two siRNA sequences for specifically knocking down the expression of the long-chain noncoding RNA are designed and synthesized; an experiment proves that after the expression level of the long-chain noncoding RNA is specifically knocked down in a human esophageal squamous carcinoma cell strain, the quantity of migrated tumor cells is remarkably reduced; therefore the siRNA sequences disclosed by the invention is also expected to be used as a molecular targeting treatment tool for inhibiting the cell migration rate of the esophageal squamous carcinoma.

Squamous carcinoma stem cells (SCSC) are identified. The cells can be prospectively isolated or identified from primary tumor samples, and are shown to possess the unique properties of cancer stem cells in functional assays for cancer stem cell self-renewal and differentiation, and to form unique histological microdomains useful in cancer diagnosis.

The invention relates to an application of amlodipine to the preparation of medicaments for curing phoproliferative diseases. The amlodipine is selected from racemic amlodipine, levorotatory amlodipine and pharmaceutically acceptable salts, and the phoproliferative diseases particularly refer to various malignant tumors, such as leukemia, lung cancer, gastric cancer, liver cancer, ovarian cancer, prostatic cancer, cervical cancer, breast cancer and squamous carcinoma.

The invention discloses an esophageal squamous carcinoma radical postoperative patient prognosis prediction model construction method and device, and the method comprises the steps: obtaining clinical diagnosis and treatment data and follow-up visit survival data, carrying out multi-factor Cox regression analysis on patient characteristic variables, tumor pathology characteristic variables, treatment condition variables and test index variables according to follow-up visit survival data, carrying out variable screening by utilizing a step-by-step back algorithm and an Akaike information criterion, and carrying out variable screening on the screened candidate variables again to obtain modeling variables; and performing multi-factor Cox regression analysis on modeling variables and interaction items of every two modeling variables to construct a prognosis prediction model of a patient after the esophageal squamous carcinoma radical operation, wherein the prediction variables comprise age, gender, tumor primary position, T stage, lymph node detection number, tumor size, preoperative hemoglobin level and N stage treatment mode interaction items. According to the method, the prediction accuracy can be improved, the optimal benefit group of different treatment schemes is defined, and the prognosis evaluation precision of the esophageal squamous cell carcinoma is realized.